NLS Pharmaceutics AG (NLSP)

NASDAQ: NLSP · IEX Real-Time Price · USD
0.270
-0.031 (-10.37%)
At close: Mar 18, 2024, 4:00 PM
0.272
+0.002 (0.82%)
After-hours: Mar 18, 2024, 7:30 PM EDT
-10.37%
Market Cap 9.98M
Revenue (ttm) n/a
Net Income (ttm) -15.47M
Shares Out 35.67M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 543,207
Open 0.320
Previous Close 0.301
Day's Range 0.220 - 0.349
52-Week Range 0.220 - 1.600
Beta -0.72
Analysts Hold
Price Target n/a
Earnings Date May 3, 2024

About NLSP

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of AD... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2021
Employees 6
Stock Exchange NASDAQ
Ticker Symbol NLSP
Full Company Profile

Financial Performance

Financial Statements

News

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

4 days ago - Accesswire

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

7 days ago - Accesswire

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disc...

24 days ago - Accesswire

Notice of Deficiency with Nasdaq Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco...

2 months ago - Accesswire

NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, SWITZERLAND / ACCESSWIRE / December 29, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery ...

2 months ago - Accesswire

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and al...

3 months ago - Accesswire

NLS Pharmaceutics Announces Election of Additional Board Members

Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders Professor Flor...

3 months ago - Accesswire

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery a...

4 months ago - Accesswire

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

NLS has executed a non-binding term sheet for licensing of NLS intellectual property NLS has secured an additional bridge loan through insiders to extend cash runway NLS has implemented significant in...

4 months ago - Accesswire

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

ZURICH, SWITZERLAND / ACCESSWIRE / October 25, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP,NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

5 months ago - Accesswire

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery an...

5 months ago - Accesswire

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3, NLS to Webcast its Event Friday, October 20 at 11:00am ET ZURICH, SWITZERLAND / ACCESSW...

5 months ago - Accesswire

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

Shares of NLS Pharmaceutics Ltd. NLSP, +19.57% gained 12% premarket on Monday after the Swiss clinical-stage biopharma company said it would proceed with phase 3 clinical studies of Mazindol ER, a tre...

9 months ago - Market Watch

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

ZÜRICH, SWITZERLAND / ACCESSWIRE / July 3, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

9 months ago - Accesswire

NLS Pharmaceutics Releases the Results from its Annual General Meeting

ZURICH, SWITZERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d...

9 months ago - Accesswire

NLS Pharmaceutics Company Update and Webcast Today Postponed

NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swis...

9 months ago - Accesswire

CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss cl...

9 months ago - Accesswire

NLS Pharmaceutics Announces Company Update Webcast

Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am...

9 months ago - Accesswire

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

ZURICH, SWITZERLAND / ACCESSWIRE / June 15, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d...

9 months ago - Accesswire

NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol

Very low risk for drug-drug interactions (DDI) with Mazindol ER based upon results from in vitro metabolism and transporter studies Demonstrated pharmacological differentiation versus currently availa...

9 months ago - Accesswire

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery ...

11 months ago - Accesswire

NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023

Oral presentation sharing significant phase 2 results of Mazindol ER in Adults with Narcolepsy Type 1 and Type 2 Five abstracts demonstrating NLS focus on and investment in hypersomnia disorders and r...

11 months ago - Accesswire

NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

ZURICH, SWITZERLAND / ACCESSWIRE / May 2, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and dev...

11 months ago - Accesswire

NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology

ZURICH, SWITZERLAND / ACCESSWIRE / April 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

11 months ago - Accesswire

NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2

Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the open label extension (OLE) study Patients treated with placebo in the randomi...

1 year ago - Accesswire